Post‑transplant lymphoproliferative disorder in hematopoietic stem cell transplant patients: A single center retrospective study between 2005 and 2012

Molecular Medicine Reports
Joana Marinho-DiasHugo Sousa

Abstract

Post‑transplant lymphoproliferative disorder (PTLD), despite its rarity, is an important mortality/morbidity event in transplant patients. The purpose of the present study was to retrospectively examine the clinical and pathologic characteristics, and outcomes of PTLD at the Portuguese Oncology Institute of Porto. A retrospective review of patient information was performed for patients that developed PTLD following allogeneic hematopoietic stem cell transplant (aHSCT) and were diagnosed between 2005 and 2012. The present study included a total of 15 patients, 8 females (53.3%) and 7 males (46.7%), with different clinicopathological characteristics. The most frequent clinical condition inducing aHSCT was acute lymphocytic leukemia (40.0%). Conditioning regimens consisted primarily in busulfan and cyclophosphamide, with anti‑thymocyte globulin, and myeloablation was the preferential treatment. Epstein‑Barr virus (EBV) was present in all patients with a median time of diagnosis following transplant of 75 days (range, 25‑485 days) and a median viral load of 4.75 log10 copies/ml (range, 3.30‑6.26 log10 copies/ml). PTLD diagnosis was mainly assessed by clinical findings, and histological confirmation was available for 5 patients: 3 m...Continue Reading

References

Nov 24, 2005·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·D P FunchM D Pescovitz
Oct 20, 2006·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·S CaillardUNKNOWN French PTLD Working Group
Jun 30, 2009·Transplant Infectious Disease : an Official Journal of the Transplantation Society·J StyczynskiP Ljungman
Jan 28, 2010·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·U AllenUNKNOWN AST Infectious Diseases Community of Practice
Mar 9, 2010·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·Lucie KalinovaPetr Bachleda
Apr 2, 2010·Journal of Korean Medical Science·Jung-Hye ChoiHo-Jin Shin
May 4, 2010·Journal of Korean Medical Science·Min Joo KimByoung Kook Kim
Jun 26, 2010·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Krzysztof MuchaLeszek Paczek
May 10, 2012·Advances in Hematology·Hazem A H Ibrahim, Kikkeri N Naresh
Jun 12, 2013·Postȩpy higieny i medycyny doświadczalnej·Ewelina GrywalskaJacek Roliński
Jan 9, 2014·Annals of Transplantation : Quarterly of the Polish Transplantation Society·Lan LuoChunji Gao
Jul 19, 2014·Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology·Altay AtalayHüseyin Kılıç
Jul 2, 2016·Haematologica·Jan StyczynskiUNKNOWN Sixth European Conference on Infections in Leukemia, a joint venture of the Infectious Diseases Working Party of the Europea

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.